$INM

Mentari Therapeutics raised an additional $200 million via a private placement ahead of its planned merger with InMed Pharmaceuticals (NASDAQ:INM). The deal also closes alongside a previously announced $290 million private placement. Funds extend Mentari’s cash runway into 2029 to support Phase 2a readouts for PACAP-targeted programs, including MT-002. Post-merger, the company will trade on Nasdaq under a new ticker.

InMed Pharmaceuticals (INM) rose in pre-market after merger partner Mentari Therapeutics announced a $200 million private placement of common stock and pre-funded warrants. Mentari said the funds extend its runway to 2029 and support Phase 2a readouts for PACAP programs, including MT-002. The all-stock merger with InMed is expected to close in 2H 2026.

Vivo Opportunity, LLC purchased 20,546 indirectly-held shares of InMed Pharmaceuticals Inc. (INM) at $1.55 across 6 trades over 2026-07-14 to 2026-07-16.

InMed Pharmaceuticals Inc. (INM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001728328 0001728328 2026-07-06 2026-07-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

InMed Pharmaceuticals (NASDAQ: INM) said it amended a previously announced all-stock merger agreement with privately held Mentari Therapeutics and its merger subsidiaries. InMed filed a preliminary Form S-4 with the SEC for the deal. The boards approved; closing is expected in Q4 2026, pending shareholder approvals and S-4 effectiveness.

Vivo Opportunity, LLC purchased 6,551 indirectly-held shares of InMed Pharmaceuticals Inc. (INM) at an average of $1.55 ($1.54–$1.55) across 6 trades over 2026-06-30 to 2026-07-02.

Vivo Opportunity, LLC purchased 249,227 indirectly-held shares of InMed Pharmaceuticals Inc. (INM) at an average of $1.57 ($1.52–$1.69, $0.39M total) across 18 trades over 2026-05-20 to 2026-06-08.

InMed Pharmaceuticals (NASDAQ: INM) said Nasdaq notified it on June 3, 2026 that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) after its closing bid stayed at or above $1.00 for 10 straight business days (May 19–June 2). Nasdaq had flagged a failure to meet the $1.00 minimum for 30 days ending March 27. Nasdaq said the matter is closed.

InMed Pharmaceuticals (INM) has received a Nasdaq notification for noncompliance with the minimum bid price requirement, as its shares traded below $1.00 for 30 consecutive days. The company has 180 days to regain compliance, with a possible 180-day extension, to avoid delisting. An analyst rates INM as a Hold with a $0.64 price target, while TipRanks' AI Analyst, Spark, rates it as Neutral due to weak financial performance and a bearish technical trend.

InMed Pharmaceuticals Inc. (NASDAQ: INM) announced it received a notice from Nasdaq regarding its failure to meet the minimum $1.00 bid price requirement for continued listing. The company's common stock traded below this threshold for 30 consecutive trading days between February 11, 2026, and March 26, 2026. InMed has 180 calendar days to regain compliance, and its shares will continue to trade on The Nasdaq Capital Market under the symbol "INM" while it explores options to cure the deficiency.